ClinicalTrials.gg
CompletedNCT07710638Updated Oct 9, 2026

Efficacy of Ivermectin in the Treatment of Plane Warts

A Phase 2 interventional study of Ivermectin and Placebo in Plane Warts, sponsored by Al-Azhar University. Completed at 1 site in Egypt. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Al-Azhar University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Jun 2025, registered Jul 2026).
Updated Oct 9, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Warts with a site in Egypt — 5 open to participants now, 5 under way, 1 of them phase 3. Warts · Egypt.

Enrollment
6th of 26
80 · median 62
Started
2025
with 1 other
Phase 2
6 of 30
1 open now
Registered
29th of 30
by date
Lead sponsor
1 of 30
Al-Azhar University

Among the 30 studies in Warts with a site in Egypt, this one is the 6th largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 2, and was the 29th registered.

Warts

172 studies on the registry are indexed under Warts; 36 are open to participants now.

Browse Warts studies →

Open to participants now

5 of the 30 studies in Warts with a site in Egypt are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 19 Warts studies recruiting now, 11 (58%) set no upper age limit and 8 (42%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 5 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Warts with a site in Egypt, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy of ivermectin in the treatment of plane warts( flat warts). patients diagnosed with plane warts will be included to assess the clearance ratre of the lesions.

03

Conditions studied

  • Plane Warts

Browse trials for

Keywords

  • ivermectin
04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: • Clinical and dermoscopic diagnosis of the plane warts.

  • No prior treatment for warts in the last 4 weeks.
  • Patients of both sex (male - female)
  • Age more than 5 years or weight more than 15 kg.

Exclusion Criteria:

    • Patients with other types of warts (e.g., common, plantar, genital).

      • History of or allergy to ivermectin or its components.
      • Patients who have received systemic therapy within the last 3 months.
      • Presence of chronic skin conditions that may interfere with evaluation (e.g., eczema, psoriasis).
      • Patients with immunodeficiency disorders (e.g., , organ transplant recipients).
      • Pregnant or lactating females.
      • Patients currently on systemic antiviral or immunomodulatory treatment.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Group1 : topical ivermectin

    Patients will receive topical ivermectin cream applied twice daily to plane warts for 3 months

    Drug: Ivermectin

  • Experimental
    Group 2 : oral ivermectin

    Patients will receive oral ivermectin once weekly for 3 months

    Drug: Ivermectin

  • Placebo comparator
    control group 1

    Other: Placebo

  • Placebo comparator
    control group 2

    Other: Placebo

Interventions

  • An antiparasitic medication evaluated for its immunomodulatory and antiviral efficacy in clearing plane warts. it will be administered to patients according to their assigned group protocol.

  • OtherPlacebo

    Patients in the control group will receive placebo,they will undergo standard clinical observation and follow up to monitor the natural course of the plane warts.

06

What researchers measure

Primary outcomes

  1. percentage of patients achieving complete clearance of plane warts

    Time frame: 3 months

07

Study locations

1 site
  • Department of Dermatology , Al-Azhar university hospital
    Asyut, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Jul 2026, 13 months.

Of 18 phase 2 interventional studies under Warts, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 23. This study's 13 months is close to that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Jun 2026 → Jun 2025, primary completion Jun 2026 → Jul 2026 and completion Jun 2027 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartActual
Jun 1, 2025was Jun 2026
Primary completionActual
Jul 1, 2026was Jun 2026
CompletionActual
Jul 1, 2026was Jun 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 9, 2026
Start date
Jun 1, 2026→Jun 1, 2025
Oct 9, 2026
Primary completion
Jun 1, 2026→Jul 1, 2026
Oct 9, 2026
Study completion
Jun 2027→Jul 1, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Active, not recruiting→Completed
    Start date Jun 1, 2026→Jun 1, 2025
    Primary completion Jun 1, 2026→Jul 1, 2026
    Study completion Jun 2027→Jul 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07710638
Responsible party
Sarah Alfoully Ahmed (Resident of dermatology, Al-Azhar University) — Principal investigator
First posted
Jul 17, 2026
Start date
Jun 1, 2025
Primary completion
Jul 1, 2026
Completion
Jul 1, 2026
Last update
Oct 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion